Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Surgeon General
  • Cigna’s ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

TRENDING TOPICS:

  • Surgeon General
  • Cigna's ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Sep 2 2015

Full Issue

Personalized Medicine Not Yet A Help For Many Health Questions

Genetic testing can still only say so much about how you will react to certain drugs, one writer finds. Elsewhere, a digital stethoscope shows promise, and Pfizer's bid to get a Medicaid overcharging complaint tossed out runs into a roadblock.

NPR: Are Statins Bad For Me? Personalized Medicine Can't Yet Say

About 25 to 30 percent of people prescribed statins dump them within a year. I flunked Lipitor after a few wretched months. Statins are prescribed to lower cholesterol in people who show risk factors for cardiovascular disease or diabetes, or who already have them. Side effects can include muscle weakness, diabetes onset and, rarely, permanent muscle damage. ... Frustrated with trial and error, I was ready to swap some DNA for some personalized insight. (Wolfson, 9/1)

The Washington Post: Eko’s Stethoscope Shows The Potential Of Digital Technology To Reinvent Health Care

About 200 years ago a French physician rolled a sheet of paper into a cylinder and held it up to the chest of a patient. The creation was crude and simple, but it worked. Rene Laenneac could better hear his patient’s heartbeat, and the stethoscope was born. Today, the stethoscope remains a fixture in medicine, draped around the shoulders of doctors. It’s also overdo for a makeover. Now Eko Devices, a Silicon Valley start-up, has received FDA approval for its digital stethoscope, which brings the power of modern technology to an already essential device. (McFarland, 9/2)

The Wall Street Journal: Pfizer Suffers Setback In Trying To Toss Medicaid Lawsuit

A federal judge said Tuesday he has an “inclination” to deny Pfizer Inc.’s four-year-old request to throw out a Justice Department lawsuit accusing the drug maker’s Wyeth unit of overcharging government Medicaid health programs for the heartburn drug Protonix, according to a federal court website. (Loftus, 9/1)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF